Aptar Active Material Science has reached an important milestone with the first two commercial launches of Activ-Film™ technology in a fishbone blister format in China. The two recent drug approvals represent the continued expansion of Aptar’s active material science solutions in the region and build on previous regulatory approvals for Aptar’s technologies across oral solid dosage forms, implantables, and diagnostic products.

Both launches support a newly commercialized antifungal therapy for adult and pediatric patients, helping make high-quality generic antifungal treatments more widely available in China. Powered by Aptar’s 3-Phase Activ-Polymer™ platform, Activ-Film™ is integrated into the blister packaging to create a controlled microclimate that supports drug product stability and performance throughout shelf life.

“The launch of this drug with our Activ-Film™ technology in China marks an important milestone in our mission to expand global use of material science to advance drug delivery performance and patient experience,” said Badre Hammond, Vice President of Commercial Operations and GM of Aptar Active Material Science.

Aptar’s pharmaceutical partners highlighted the value of collaboration with Aptar, noting that Activ-Film™ technology helps safeguard product integrity, streamline commercialization efforts, and support portfolio growth.

These recent commercial successes highlight Aptar’s growing momentum in China and showcase the strong foundation being established in the region. Together, they demonstrate increasing adoption of Aptar’s active material science solutions as we continue to expand our global footprint.